RxDoctor Payments Data

Anna Mendoza, MD

Family Medicine · Delano, CANPI 1699742510

Payments from drug & device makers

$693in general payments, 2019–2025

Across 20 payments — averaging $34.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$275
  • Lilly USA, LLC$109
  • Johnson & Johnson$77
  • Pfizer$64
  • Merck$58
  • AstraZeneca$48
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$41860%
  • Education$27540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$693 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$23,511
Medicare patients
155
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin257$228,454
TradjentaLinagliptin146$117,800
JanuviaSitagliptin Phosphate91$103,750
FarxigaDapagliflozin Propanediol69$64,593
OzempicSemaglutide66$59,889
EliquisApixaban36$32,667
ProliaDenosumab14$23,130
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog64$16,941
LinzessLinaclotide14$13,722
Atorvastatin Calcium808$8,193
EntrestoSacubitril/Valsartan11$6,868
DapagliflozinDapagliflozin Propanediol12$6,004
Praluent PenAlirocumab13$5,965
Losartan Potassium620$5,834
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$5,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$37$346,254403 claims
MerckJanuvia$58$103,75091 claims
AstraZenecaFarxiga$48$64,59369 claims
PfizerEliquis$64$32,66736 claims
Lilly USA, LLCHumulin 70-30$109$1,36811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Delano

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →